{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:51:16Z","timestamp":1792511476960,"version":"4.5.0"},"reference-count":91,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2019,7,27]],"date-time":"2019-07-27T00:00:00Z","timestamp":1564185600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2020,1]]},"abstract":"<jats:p>The development of BCR-ABL-targeting tyrosine kinase inhibitors has transformed chronic phase chronic myeloid leukemia (CP CML) from a disease with a terminal prognosis to a treatable chronic illness. Long-term treatment with tyrosine kinase inhibitors means that patients have to be clinically managed and monitored over extended periods of time, thus a patient-centered, medically integrated, and multidisciplinary oncology healthcare team is required to support patients through their journey. Pharmacists work with patients, physicians, and the wider support team to select the optimum therapy plan for a given patient. These decisions are based on risk factors, comorbidities, concomitant medications, and personal circumstances and pharmacists advise on the efficacy and safety of different treatment options. Additionally, pharmacists are a key point-of-contact and resource for monitoring patient response to treatment, identifying and managing adverse events and drug\u2013drug interactions, any subsequent therapy plan modifications, and, potentially, treatment-free remission. Pharmacists also assist with patient education, medication adherence, and financial discussions with patients throughout the long course of the disease. This review provides an overview of BCR-ABL tyrosine kinase inhibitors, discusses the role of the medically integrated pharmacy team, and suggests strategies that pharmacists can use in patient management and clinical decision-making to optimize the treatment of CP CML.<\/jats:p>","DOI":"10.1177\/1078155219864640","type":"journal-article","created":{"date-parts":[[2019,7,27]],"date-time":"2019-07-27T05:07:03Z","timestamp":1564204023000},"page":"156-174","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":6,"title":["Front-line use of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia: Practice considerations"],"prefix":"10.1177","volume":"26","author":[{"given":"Michael J","family":"Reff","sequence":"first","affiliation":[{"name":"National Community Oncology Dispensing Association, Inc., Cazenovia, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Shillingburg","sequence":"additional","affiliation":[{"name":"Clinical Pharmacy Services and PGY2 Oncology Pharmacy Residency, Levine Cancer Institute, Charlotte, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhavesh","family":"Shah","sequence":"additional","affiliation":[{"name":"Specialty and Hematology-Oncology Pharmacy Services, Boston Medical Center, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Elder","sequence":"additional","affiliation":[{"name":"The Lloyd L. Gregory School of Pharmacy, Palm Beach Atlantic University, Gregory School of Pharmacy, West Palm Beach, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hillary","family":"Prescott","sequence":"additional","affiliation":[{"name":"Clinical Pharmacy Services and PGY2 Oncology Pharmacy Residency, Dana Farber Cancer Institute, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Kennerly-Shah","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Ohio State University Medical Center, Columbus, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2019,7,27]]},"reference":[{"key":"bibr1-1078155219864640","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25011"},{"key":"bibr2-1078155219864640","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-018-0449-7"},{"key":"bibr3-1078155219864640","unstructured":"National Cancer Institute. Cancer Stat Facts: Leukemia \u2013 Chronic Myeloid Leukemia (CML), https:\/\/seer.cancer.gov\/statfacts\/html\/cmyl.html (accessed 6 March 2019)."},{"key":"bibr4-1078155219864640","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: chronic myeloid leukemia, www.nccn.org\/professionals\/physician_gls\/pdf\/cml.pdf (accessed 6 March 2019)."},{"key":"bibr5-1078155219864640","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2016.10.005"},{"key":"bibr6-1078155219864640","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(15)00048-4"},{"key":"bibr7-1078155219864640","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.66.2866"},{"key":"bibr8-1078155219864640","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.4663"},{"key":"bibr9-1078155219864640","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13637"},{"key":"bibr10-1078155219864640","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0000000000000165"},{"key":"bibr11-1078155219864640","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24887"},{"key":"bibr12-1078155219864640","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-017-0404-z"},{"key":"bibr13-1078155219864640","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2017.11.006"},{"key":"bibr14-1078155219864640","first-page":"42","volume":"7","author":"Bauer S","year":"2016","journal-title":"J Adv Pract Oncol"},{"key":"bibr15-1078155219864640","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.3087"},{"key":"bibr16-1078155219864640","doi-asserted-by":"publisher","DOI":"10.1177\/1078155217710553"},{"key":"bibr17-1078155219864640","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1P784"},{"key":"bibr18-1078155219864640","doi-asserted-by":"publisher","DOI":"10.18549\/PharmPract.2015.02.559"},{"key":"bibr19-1078155219864640","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.22019"},{"key":"bibr20-1078155219864640","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.082511"},{"key":"bibr21-1078155219864640","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-309807"},{"key":"bibr22-1078155219864640","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022457"},{"key":"bibr23-1078155219864640","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609324"},{"key":"bibr24-1078155219864640","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002315"},{"key":"bibr25-1078155219864640","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.8899"},{"key":"bibr26-1078155219864640","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0912614"},{"key":"bibr27-1078155219864640","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.5"},{"key":"bibr28-1078155219864640","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.74.7162"},{"key":"bibr29-1078155219864640","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.7002"},{"key":"bibr30-1078155219864640","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.7522"},{"key":"bibr31-1078155219864640","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13108"},{"key":"bibr32-1078155219864640","unstructured":"US Food and Drug Administration. Highlights of prescribing information: Sprycel (dasatinib), www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/021986s7s8lbl.pdf (accessed 6 March 2019)."},{"key":"bibr33-1078155219864640","unstructured":"US Food and Drug Administration. Highlights of prescribing information: Tasigna (nilotinib), www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/022068s004s005lbl.pdf (accessed 6 March 2019)."},{"key":"bibr34-1078155219864640","unstructured":"US Food and Drug Administration. Highlights of prescribing information: Bosulif (bosutinib), www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/203341s009lbl.pdf (accessed 6 March 2019)."},{"key":"bibr35-1078155219864640","unstructured":"US Food and Drug Administration. Highlights of prescribing information: Gleevec (imatinib mesylate), www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/021588s053lbl.pdf (accessed 6 March 2019)."},{"key":"bibr36-1078155219864640","unstructured":"European Medicines Agency. Summary of product characteristics: Bosulif (bosutinib), https:\/\/www.ema.europa.eu\/documents\/product-information\/bosulif-epar-product-information_en.pdf (accessed 6 March 2019)."},{"key":"bibr37-1078155219864640","unstructured":"European Medicines Agency. Summary of product characteristics: Imatinib medac, www.ema.europa.eu\/documents\/product-information\/imatinib-medac-epar-product-information_en.pdf (accessed 6 March 2019)."},{"key":"bibr38-1078155219864640","unstructured":"European Medicines Agency. Summary of product characteristics: Sprycel (dasatinib), www.ema.europa.eu\/documents\/product-information\/sprycel-epar-product-information_en.pdf (accessed 6 March 2019)."},{"key":"bibr39-1078155219864640","unstructured":"European Medicines Agency. Summary of product characteristics: Tasigna (nilotinib), www.ema.europa.eu\/documents\/product-information\/tasigna-epar-product-information_en.pdf (accessed 6 March 2019)."},{"key":"bibr40-1078155219864640","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V63.4.789.789"},{"key":"bibr41-1078155219864640","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/90.11.850"},{"key":"bibr42-1078155219864640","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12356"},{"key":"bibr43-1078155219864640","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-05-501569"},{"key":"bibr44-1078155219864640","doi-asserted-by":"publisher","DOI":"10.1586\/17474086.2013.837279"},{"key":"bibr45-1078155219864640","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-01-617993"},{"key":"bibr46-1078155219864640","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2018.01.004"},{"key":"bibr47-1078155219864640","doi-asserted-by":"publisher","DOI":"10.2147\/VHRM.S108874"},{"key":"bibr48-1078155219864640","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.104"},{"key":"bibr49-1078155219864640","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.6557"},{"key":"bibr50-1078155219864640","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-114900"},{"key":"bibr51-1078155219864640","doi-asserted-by":"publisher","DOI":"10.4084\/mjhid.2014.028"},{"key":"bibr52-1078155219864640","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.866662"},{"key":"bibr53-1078155219864640","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2014.10.002"},{"key":"bibr54-1078155219864640","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2017.1347929"},{"key":"bibr55-1078155219864640","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24186"},{"key":"bibr56-1078155219864640","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2009.n.064"},{"key":"bibr57-1078155219864640","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-015-2317-z"},{"key":"bibr58-1078155219864640","first-page":"4","volume":"2012","author":"Pavlovsky C","year":"2012","journal-title":"Case Rep Hematol"},{"key":"bibr59-1078155219864640","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V114.22.4270.4270"},{"key":"bibr60-1078155219864640","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-03-490003"},{"key":"bibr61-1078155219864640","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2018.1467919"},{"key":"bibr62-1078155219864640","first-page":"SP500","volume":"23","author":"Nubla J","year":"2017","journal-title":"Am J Manag Care"},{"key":"bibr63-1078155219864640","doi-asserted-by":"publisher","DOI":"10.1016\/j.japh.2017.01.004"},{"key":"bibr64-1078155219864640","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.17.00039"},{"key":"bibr65-1078155219864640","doi-asserted-by":"publisher","DOI":"10.1177\/1078155215608523"},{"key":"bibr66-1078155219864640","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-017-0958-6"},{"key":"bibr67-1078155219864640","doi-asserted-by":"publisher","DOI":"10.1177\/1078155218759184"},{"key":"bibr68-1078155219864640","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-016-3486-6"},{"key":"bibr69-1078155219864640","first-page":"SP33","volume":"5","author":"Visaria J","year":"2013","journal-title":"Am J Pharm Benefits"},{"key":"bibr70-1078155219864640","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp150749"},{"key":"bibr71-1078155219864640","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V118.21.603.603"},{"key":"bibr72-1078155219864640","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.68.2914"},{"key":"bibr73-1078155219864640","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.48.5797"},{"key":"bibr74-1078155219864640","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V122.21.4020.4020"},{"key":"bibr75-1078155219864640","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-02-483750"},{"key":"bibr76-1078155219864640","doi-asserted-by":"crossref","unstructured":"Clark RE, Polydoros F, Apperley JF, et\u00a0al. Initial reduction of therapy before complete withdrawal improves the chance of successful treatment discontinuation in chronic myeloid leukaemia (CML): year 2 results in the British Destiny study, https:\/\/learningcenter.ehaweb.org\/eha\/2017\/22nd\/181710\/richard.clark.initial.reduction.of.therapy.before.complete.withdrawal.improves.html (accessed 6 March 2019).","DOI":"10.1016\/S2352-3026(19)30094-8"},{"key":"bibr77-1078155219864640","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.63"},{"key":"bibr78-1078155219864640","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.787.787"},{"key":"bibr79-1078155219864640","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2018.03.004"},{"key":"bibr80-1078155219864640","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-09-742205"},{"key":"bibr81-1078155219864640","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.1895.1895"},{"key":"bibr82-1078155219864640","first-page":"2875","volume":"130","author":"Ritchie EK","year":"2017","journal-title":"Blood"},{"key":"bibr83-1078155219864640","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1182\/blood.V128.22.791.791","volume":"128","author":"Kumagai T","year":"2016","journal-title":"Blood"},{"key":"bibr84-1078155219864640","unstructured":"Rousselot P, Etienne G, Coiteux V, et\u00a0al. Attempt to early discontinue dasatinib first line in chronic phase CML patients in early molecular response and included in the prospective OPTIM-dasatinib trial, https:\/\/learningcenter.ehaweb.org\/eha\/2015\/20th\/100740\/philippe.rousselot.attempt.to.early.discontinue.dasatinib.first.line.in.html (accessed 6 March 2019)."},{"key":"bibr85-1078155219864640","doi-asserted-by":"publisher","DOI":"10.7326\/M17-1094"},{"key":"bibr86-1078155219864640","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.194894"},{"key":"bibr87-1078155219864640","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.790.790"},{"key":"bibr88-1078155219864640","doi-asserted-by":"crossref","first-page":"3094","DOI":"10.1182\/blood.V128.22.3094.3094","volume":"128","author":"Rea D","year":"2016","journal-title":"Blood"},{"key":"bibr89-1078155219864640","first-page":"1622","volume":"130","author":"Kim D","year":"2017","journal-title":"Blood"},{"key":"bibr90-1078155219864640","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24120"},{"key":"bibr91-1078155219864640","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V122.21.4003.4003"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155219864640","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1078155219864640","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155219864640","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:21:34Z","timestamp":1777688494000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1078155219864640"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,27]]},"references-count":91,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["10.1177\/1078155219864640"],"URL":"https:\/\/doi.org\/10.1177\/1078155219864640","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,27]]}}}